Retatrutide
Phase 3aka LY3437943
Triple agonist (GLP-1, GIP, glucagon) in phase 3 for obesity. The one everyone's watching.
Mechanism
One molecule hitting three metabolic receptors at once: GLP-1, GIP, and glucagon. The glucagon arm is the interesting part, it bumps energy expenditure on top of the appetite suppression you already get from a GLP-1. On paper it should out-cut tirzepatide, and the phase 2 numbers backed that up.
Regulatory & Safety Status
Still investigational. Lilly's compound, no regulator has signed off, so everything you read is trial data. Anything sold to you right now is grey market.
Research
GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists
Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians
Retatrutide: Triple acting jab for type 2 diabetes lowers blood sugar and boosts weight loss, trial reports
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
Retatrutide phase 2 obesity trial
Phase 2 RCT reporting dose-dependent weight reduction over 48 weeks.
Latest retatrutide research